Feedback PLC Appointment of non-executive director (9477K)
16 April 2018 - 8:25AM
UK Regulatory
TIDMFDBK
RNS Number : 9477K
Feedback PLC
16 April 2018
This announcement contains inside information as stipulated
under the Market Abuse Regulation (EU) No 596/2014 (MAR).
16 April 2018
Feedback Plc
("Feedback" or the "Company")
Appointment of non-executive director
Cambridge, UK - 16 April 2018: Feedback plc ("Feedback" or the
"Company") (AIM: FDBK), the specialist medical imaging technology
company, announces the appointment of Simon Sturge as Non-Executive
Director with immediate effect.
Mr Sturge joined Merck Healthcare in 2014 and is currently Chief
Operating Officer and member of the Healthcare Executive Committee.
He is an experienced healthcare executive in the UK and has built a
very strong reputation not only in the biotechnology industry but
also in the investment community. His experience includes eight
years at Celltech, and he was the founder and CEO of RiboTargets
which later reversed into Vernalis Plc. After serving as CEO of
OctoPlus N.V. for two years, he became Senior Vice President of
Boehringer Ingelheim's Biopharmaceutical Business. Mr Sturge is a
regular speaker at conferences including the World Economic
Forum.
Dr Alastair Riddell, Chairman of Feedback, said: "Since joining
Feedback I have been impressed by the potential of its products in
improving patient management. As the Company transforms into a
unified structure with a focus on commercial development, it will
benefit greatly from the vision, experience and breadth of reach of
Simon in the healthcare field to help realise its full
potential."
Simon Sturge, Non-Executive Director of Feedback, commented: ""I
am very excited to have the opportunity to join the Board of
Feedback. We see that in many fields of healthcare there is
substantial value in being a depositary of a large volume of data
and even more value in being able to intelligently interpret such
data. I truly feel that textural mapping of tumours will have a
significant impact on the way we undertake the development of new
pharmaceutical products to increase focus toward personalised
treatments as well as improving the diagnosis and treatment of
cancer. I believe that Feedback has an advantage in being an early
mover in this field and look forward to taking on an active role as
a non-executive director in shaping this next stage in the
Company's development."
Regulatory Disclosures
In accordance with Rule 17 and Schedule 2(g) of the AIM Rules
for Companies, Simon John Sturge, aged 59 is, or has been within
the last five years, a director or partner in the following
companies and partnerships:
Current directorships and partnerships Past directorships and partnerships
held within the last five years
Cristal Therapeutics BV Silence Therapeutics plc
Simon Sturge currently holds 6,000,000 ordinary shares in the
Company, equivalent to 2.13 per cent of the Company's total issued
ordinary share capital.
There is no other information required to be disclosed under the
AIM Rules for Companies.
Notes to editors
About Feedback plc
Feedback plc is a specialist medical imaging technology company.
It develops software and systems that provide innovative techniques
and improved workflows for practitioners involved in medical
research and treating patients. TexRAD(R) , the Company's patented
quantitative image texture analysis technology, has the potential
to assist clinicians in diagnosis, prognosis and treatment of
patients with cancer and is currently installed in over 40 of the
world's leading research institutions across Europe, North America,
Asia and Australasia. The Cadran platform provides a suite of
medical imaging tools for decision support. The Cadran range
includes the picture archiving communication system (PACS) to
provide decision support for scan analysis, diagnostic workstations
which provide secure remote access to view scans on demand, and
products to securely share and transport patient data. Visit
www.fbk.com.
For further information, please contact:
Feedback plc Tel: 01954 718072
David Crabb, Chief Executive Officer IR@fbk.com
Lara Mott, Investor Relations
Allenby Capital Limited (Nominated Adviser and Tel: 020 3328 5656
Joint Broker)
David Worlidge / Asha Chotai
Northland Capital Partners Ltd (Joint Broker) Tel: 020 3861 6625
David Hignell / John Howes
Peterhouse Corporate Finance Ltd (Joint Broker) Tel: 020 7469 093
Lucy Williams / Duncan Vasey
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAIAMLTMBIBBBP
(END) Dow Jones Newswires
April 16, 2018 02:25 ET (06:25 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024